Sanofi has agreed to develop Principia Biopharma’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246) for the treatment of multiple sclerosis (MS) and possibly other central nervous system (CNS) diseases.
Cerenis Therapeutics has acquired Lypro Biosciences to expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery.
Spark Therapeutics and Pfizer have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B.
Biotechnology company Recursion Pharmaceuticals is using Splunk Enterprise and the Splunk Machine Learning Toolkit to reach its target of treating 100 molecular genetic diseases by 2025.
Boehringer Ingelheim and Dicerna Pharmaceuticals have partnered to develop treatments for chronic liver diseases including Nonalcoholic Steatohepatitis (NASH).
Aviragen Therapeutics, which is engaged in the discovery and development of direct-acting antivirals to treat infections with limited therapeutic options, has signed a merger agreement with Vaxart, a clinical-stage company focused on developing oral recombinant vaccines.
Voyager Therapeutics, a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, has announced an update to its VY-AADC program for advanced Parkinson’s disease.
A major international collaboration involving hundreds of researchers worldwide has identified seventy-two new genetic variants that contribute to the risk of developing breast cancer.
Incyte and MacroGenics have entered into an exclusive global collaboration and license agreement for MacroGenics’ MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).
Aurinia Pharmaceuticals revealed plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.